Angelika Lahr

The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial

M. M. Heiss, P. Murawa, P. Koralewski et al. · International Journal of Cancer · 2010 · 551 citations · Full text

Medicine, Oncology, Pharmacotherapy +15

Effective Relief of Malignant Ascites in Patients with Advanced Ovarian Cancer by a Trifunctional Anti-EpCAM × Anti-CD3 Antibody: A Phase I/II Study

Alexander Burges, Pauline Wimberger, Carolin Kümper et al. · Clinical Cancer Research · 2007 · 257 citations

Medicine, Oncology, Pharmacology +17

First-in-Human Phase I Study of Single-agent Vanucizumab, A First-in-Class Bispecific Anti-Angiopoietin-2/Anti-VEGF-A Antibody, in Adult Patients with Advanced Solid Tumors

Manuel Hidalgo, Maria Martinez‐García, Christophe Le Tourneau et al. · Clinical Cancer Research · 2017 · 102 citations

Medicine, Oncology, Pharmacology +17

The McCAVE Trial: Vanucizumab plus mFOLFOX-6 Versus Bevacizumab plus mFOLFOX-6 in Patients with Previously Untreated Metastatic Colorectal Carcinoma (mCRC)

Johanna C. Bendell, Tamara Saurí, Antonio Cubillo Gracián et al. · The Oncologist · 2019 · 46 citations · Full text

Medicine, Oncology, Pharmacology +17

Phase 1 dose-escalation study of the antiplacental growth factor monoclonal antibody RO5323441 combined with bevacizumab in patients with recurrent glioblastoma

Ulrik Lassen, Olivier Chinot, Catherine McBain et al. · Neuro-Oncology · 2015 · 41 citations · Full text

Medicine, Oncology, Pharmacotherapy +16